Phase 2 N=154 Post-Operative Constipation Following Total Knee Arthroplasty
Constipation
Primary: Bowel Movement (BM) Within 3 Days of Surgery — 29; 32 Participants — p=0.41
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Effect of Preoperative Fiber on Postoperative Bowel Function
Constipation · Prolapse, Vaginal
Primary: Time to First Bowel Movement After Surgery — 66.5; 68.3 hours
Phase 4 N=97 Bowel Function After Minimally Invasive Hysterectomy
Constipation
Primary: Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) Score — 1.1; 0.6 score
N/A N=40 The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation · Chronic Idiopathic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Phase 4 N=120 Sugammadex To IMprove Bowel Function
Bowel Dysfunction · Postoperative Complications · Neuromuscular Blockade
Primary: Gastric Emptying — 1120; 1130 log(ng*ml-1)*min — p=0.58
Phase 1 N=41 Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Chronic Constipation, Methanogenesis
Primary: Change in Methane Production — 10645; 14635 parts per million*minutes
N/A N=8 Infracoccygeal Botox for Dyssynergia
Dyssynergic Defaecation · Evacuation Disorder · Anismus
Primary: The Rate of Identification of Puborectalis During Ultrasound Scan — 8 Participants
Phase 4 N=75 Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
Obstructive Defecation Syndrome · Chronic Constipation · Rectocele
Primary: Percentage of Change (Reduction) in Total ODS Symptom Composite Score From Baseline to One Year Post Procedure — 60.8 percentage of change
N/A N=16 Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers
Constipation · Diet Modification
Primary: Relaxation Time in Ascending Colon — 312; 256 seconds*minutes
Phase 4 N=13 Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Chronic Constipation
Primary: The Number of High-Amplitude Propagating Contractions (HAPC) — 8.7; 2.9 Number of HAPC with amplitude ≥100mmHg — p=0.012
N/A N=72 Bowel Function After Minimally Invasive Urogynecologic Surgery
Functional Disorder of Intestine
Primary: Time to First Post-op Bowel Movement — 64; 77 hours
Phase 2 N=192 Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation
Functional Constipation
Primary: Change in Colonic Transit Time From Baseline to Day 15 — -1.7; 4.0; 2.5; 2.6 Hours
N/A N=199 S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Constipation, Impaction, and Bowel Obstruction · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Number of Days Alive and Outside of the Hospital — 42.6; 43.9; 54.8; 52.7 days — p=0.50
Phase 4 N=360 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
Spinal Cord Injury
Primary: Quality of Bowel Preparation — 3.4; 2.5; 3.6; 7.4 units on a scale
N/A N=64 Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation
Constipation
Primary: Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym) — -0.22; -0.29 units on a scale — p=<0.05
Phase 2 N=36 Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation
Functional Constipation
Primary: Colonic Transit at 24 Hours — 2.68; 3.12; 1.93 units on a scale — p=0.059
N/A N=3,000 Compound Sodium Picosulfate Granules for Bowel Preparation in Chinese Population
Bowel Cleansing
Primary: Incidence of Known Adverse Drug Reactions (ADRs) — 2; 1; 2; 6 Participants
Phase 2 N=154 Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Constipation
Primary: Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration — 19.2; 31.4; 19.2 percentage of participants — p=0.1790
Phase 3 N=633 Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
Chronic Constipation
Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 13; 34; 43; 202 participants — p=0.0012
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 2 N=131 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Opioid Induced Constipation
Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week
Phase 3 N=439 Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)
Opioid-induced Bowel Dysfunction
Primary: Number of Participants Classified as Treatment Responders Within 12 Weeks — 59; 41 Participants
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 3 N=596 A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
Joint Diseases · Arthritis · Osteoarthritis
Primary: 5-Day Sum of Pain Intensity Difference (SPID5) — 98.6; 153.1; 161.8; 218.4 Units on a scale — p=0.007
Phase 3 N=643 Trial of Linaclotide in Patients With Chronic Constipation
Chronic Constipation
Primary: Complete Spontaneous Bowel Movement (CSBM) Overall Responder — 46; 42; 7 participants — p=<0.0001
Phase 3 N=437 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
Opioid-Induced Bowel Dysfunction
Primary: Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8 — 2.4; 2.6 Spontaneous Bowel…